SCHEMBL21531035

SCHEMBL21531035

CCN(CC)CCNC(=O)c1ccc(F)cc1F

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.74
MCHR1 Q99705 3/20 0.58
POLB P06746 1/20 0.56
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 2/20 0.55
HPGD P15428 1/20 0.55
ACKR3 P25106 1/20 0.52
LMNA P02545 5/20 0.51
ADRA2A P08913 3/20 0.51
CYP2D6 P10635 3/20 0.51
DRD3 P35462 3/20 0.51
TSHR P16473 2/20 0.51
DRD2 P14416 2/20 0.51
HTR2B P41595 2/20 0.51
KCNH2 Q12809 2/20 0.51
CYP2C9 P11712 1/20 0.51
STAT6 P42226 1/20 0.51
KDR P35968 1/20 0.51
SLC22A1 O15245 2/20 0.50
ACHE P22303 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30231342 0.85 ACKR3 (0.69) L3MBTL1ALDH1A1KDM4EACKR3SMN1; SMN2
SCHEMBL13753140 0.83 L3MBTL1 (0.54) L3MBTL1POLBALDH1A1HPGDACKR3
SCHEMBL21210764 0.81 HTT (0.58) L3MBTL1HPGDLMNATSHRSMN1; SMN2
SCHEMBL6068233 0.80 CES2 (0.55) L3MBTL1KDM4EACKR3LMNACYP2C19
SCHEMBL9363810 0.79 POLB (0.84) L3MBTL1MCHR1POLBALDH1A1KDM4E
SCHEMBL12438386 0.79 POLB (0.84) L3MBTL1MCHR1POLBALDH1A1KDM4E
SCHEMBL12462063 0.79 HDAC3 (0.54) L3MBTL1ACKR3LMNATSHRCYP1A2
SCHEMBL5636971 0.79 ALPL (0.55) L3MBTL1ALDH1A1KDM4EACKR3RAB9A
SCHEMBL6544758 0.78 HDAC3 (0.58) L3MBTL1ALDH1A1HPGDLMNATSHR
SCHEMBL7967927 0.78 NPC1 (0.50) L3MBTL1POLBKDM4EHPGDACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11504439-B2 Radioactive compound for diagnosis of malignant melanoma and use thereof INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2022-11-22 US disclosed
EP-3816156-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF Industry Foundation of Chonnam National University (KR) 2021-05-05 EP disclosed
US-20210113719-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2021-04-22 US disclosed
EP-3569589-A1 RADIOACTIVE COMPOUND FOR DIAGNOSIS OF MALIGNANT MELANOMA AND USE THEREOF Industry Foundation of Chonnam National University (KR) 2019-11-20 EP disclosed
US-20190336621-A1 RADIOACTIVE COMPOUND FOR DIAGNOSIS OF MALIGNANT MELANOMA AND USE THEREOF INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) 2019-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210113719-A1 RADIOACTIVE COMPOUND FOR TREATMENT OF MELANOMA AND USE THEREOF CD47, TYR, NRAS L3MBTL1 1971/4885MCHR1 128/4885POLB 2043/4885
US-20190336621-A1 RADIOACTIVE COMPOUND FOR DIAGNOSIS OF MALIGNANT MELANOMA AND USE THEREOF MITF, BRAF, MEN1 L3MBTL1 943/4885MCHR1 66/4885POLB 3939/4885
US-11504439-B2 Radioactive compound for diagnosis of malignant melanoma and use thereof MITF, BRAF, MEN1 L3MBTL1 943/4885MCHR1 66/4885POLB 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.